[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Nibu K, Sugasawa M, Asai M, Ichimura K, Mochiki M, Terahara A, Kawahara N, Asato H: Results of multimodality therapy for squamous cell carcinoma of maxillary sinus. Cancer; 2002 Mar 1;94(5):1476-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of multimodality therapy for squamous cell carcinoma of maxillary sinus.
  • BACKGROUND: A wide variety of modalities, including surgery, radiation therapy, and chemotherapy, alone or in combination, have been used for the treatment of squamous cell carcinoma (SCC) of the maxillary sinus to obtain better local control and maintain functions.
  • However, there is still much controversy with regard to the optimum treatment.
  • METHODS: From 1987 to 1999, 33 patients with SCC of maxillary sinus were treated at the Department of Otolaryngology-Head and Neck Surgery, University of Tokyo Hospital.
  • The treatment consisted of 30-40 grays (Gy) of preoperative radiotherapy with concomitant intraarterial infusion of 5-fluorouracil and cisplatin followed by surgery and 30-40 Gy of postoperative radiotherapy, for tumors without skull base invasion.
  • For tumors invading the skull base, preoperative systemic chemotherapy with or without radiotherapy was performed, instead of intraarterial chemotherapy, then followed by skull base surgery.
  • CONCLUSIONS: Our multimodal treatment has provided favorable local control and survival outcome with good functional results.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Retrospective Studies. Skull Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11920504.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Qureshi SS, Chaukar DA, Talole SD, D'Cruz AK: Squamous cell carcinoma of the maxillary sinus: a Tata Memorial Hospital experience. Indian J Cancer; 2006 Jan-Mar;43(1):26-9
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the maxillary sinus: a Tata Memorial Hospital experience.
  • BACKGROUND: The optimal treatment of maxillary sinus carcinoma remains to be defined and there is a paucity of Indian studies on the subject.
  • AIMS: To present experience of management of squamous cell carcinoma of the maxillary sinus treated with curative intent at a single institution.
  • SETTINGS AND DESIGN: Retrospective study of patients with squamous cell carcinoma of the maxillary sinus who presented between 1994 to 1999.
  • MATERIALS AND METHODS: The records of 73 patients with squamous cell carcinoma of the maxillary sinus were analyzed.
  • Forty patients (65%) were treated with surgery followed by postoperative radiotherapy, five patients (8%) were treated with radiotherapy alone, five patients (8%) were treated with surgery alone; 12 patients (19%) received chemotherapy.
  • CONCLUSIONS: The majority of patients present with advanced disease resulting in poor outcomes to conventional treatment modalities.
  • [MeSH-major] Carcinoma, Squamous Cell. Maxillary Sinus Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763359.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


3. González García R, Sastre Pérez J, Naval Gías L, Rodríguez Campo FJ, Díaz González FJ: Cavernous sinus metastasis from oropharyngeal squamous cell carcinoma. Med Oral Patol Oral Cir Bucal; 2007 Mar;12(2):E166-70
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cavernous sinus metastasis from oropharyngeal squamous cell carcinoma.
  • Metastasis to the cavernous sinus from head and neck cancer is uncommon and has been previously reported by a few authors.
  • Main clinical findings are those related with involvement of cranial nerves III to VI as they pass through the cavernous sinus.
  • Although diagnosis may be difficult, the appearance of clinical and radiological findings of cavernous sinus involvement in a context of head and neck cancer must alert us about an intracranial metastatic infiltration.
  • In most cases treatment is palliative with radiotherapy and/or chemotherapy.
  • We present the case of cavernous sinus metastasis from oropharyngeal squamous cell carcinoma and review the literature about the clinical presentation and management of this rare entity.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Cavernous Sinus. Oropharyngeal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17322808.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Yamada S, Onodera S, Yahara K, Ohguri T, Kato F, Nomoto S, Imada H, Nakata H, Terashima H, Kudoh K, Yoshida M: [Results of combined therapy for maxillary sinus squamous cell carcinoma]. Nihon Igaku Hoshasen Gakkai Zasshi; 2003 Jul;63(6):316-21
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of combined therapy for maxillary sinus squamous cell carcinoma].
  • The results of 54 cases of maxillary sinus squamous cell carcinoma treated between 1980 and 2002 were analyzed retrospectively.
  • All patients underwent combined therapy including radiotherapy, surgery, and regional or systemic chemotherapy.
  • Fifteen patients received hyperfractionated twice-daily radiotherapy (1.2 Gy or 1.5 Gy/fraction), and the remaining 39 patients received a conventional once-daily regimen(1.5-2 Gy/fraction).
  • There were no significant differences in other prognostic factors including gender, T classification (T1-3 vs. T4), hyperfractionated radiotherapy (yes vs. no), total dose (BED: < 69 Gy10 vs. > or = 69 Gy10), and intra-arterial chemotherapy(yes vs. no).
  • Although radiation-induced cataract was observed in 9 patients, no other severe late complications developed.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Dose Fractionation. Maxillary Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12934550.001).
  • [ISSN] 0048-0428
  • [Journal-full-title] Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica
  • [ISO-abbreviation] Nihon Igaku Hoshasen Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Yamashita T, Fujii M, Ishiguro R, Tashiro M, Ohno Y, Tokumaru Y, Kanke M, Imanishi Y, Tomita T, Kanzaki J, Inuyama Y: [Statistical analysis of maxillary sinus squamous cell carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2002 Jun;105(6):732-40
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Statistical analysis of maxillary sinus squamous cell carcinoma].
  • Cases of squamous cell carcinoma of the maxillary sinus initially treated at Keio University Hospital between January 1981 and December 1998 studied retrospectively involved 60 untreated cases--46 men and 14 women aged 36 to 86 years (mean: 59.8 years).
  • Of the 59, 48 (81.4%) underwent neoadjuvant chemotherapy (NAC).
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Maxillary Sinus Neoplasms / mortality. Maxillary Sinus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Proportional Hazards Models. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12138701.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Jang NY, Wu HG, Park CI, Heo DS, Kim DW, Lee SH, Rhee CS: Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity. Jpn J Clin Oncol; 2010 Jun;40(6):542-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiotherapy with or without chemotherapy for T3-4N0 squamous cell carcinoma of the maxillary sinus and nasal cavity.
  • OBJECTIVE: To evaluate the efficacy and toxicity of definitive radiotherapy with or without chemotherapy for T3-4 squamous cell carcinoma of maxillary sinus and nasal cavity.
  • METHODS: Forty-two patients with T3-4N0 squamous cell carcinoma of maxillary sinus (n = 30) and nasal cavity (n = 12) received definitive radiotherapy.
  • Chemotherapy was used in 34 patients and elective neck irradiation was not used.
  • RESULTS: The 5-year overall survival/local control rates were 34%/29% for maxillary sinus cancer and 50%/52% for nasal cavity cancer.
  • For maxillary sinus cancers, a performance status of Eastern Cooperative Oncology Group >or=2 (P = 0.012), biologically equivalent dose <68 Gy (P = 0.011) and no use of chemotherapy (P = 0.037) were significant worse predictors for overall survival on log-rank analysis.
  • Biologically equivalent dose <68 Gy was independently associated with poor local control (hazard ratio, 3.32; 95% confidence interval, 1.38-7.97; P = 0.007) and overall survival (hazard ratio, 2.94; 95% confidence interval, 1.23-7.01; P = 0.015).
  • Regional recurrence occurred in only 1 of 30 patients with maxillary sinus cancer and 4 of 12 patients with nasal cavity.
  • CONCLUSIONS: The treatment outcome was poor and local control was a major problem.
  • High radiation dose, effective chemotherapy and elective neck irradiation for advanced nasal cavity cancers may improve disease control.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Maxillary Sinus Neoplasms / radiotherapy. Nasal Cavity. Nose Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Palliative Care. Prognosis. Radiation Injuries. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185459.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


7. Ogawa K, Toita T, Kakinohana Y, Adachi G, Kojya S, Itokazu T, Shinhama A, Matsumura J, Murayama S: Postoperative radiotherapy for squamous cell carcinoma of the maxillary sinus: analysis of local control and late complications. Oncol Rep; 2001 Mar-Apr;8(2):315-9
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative radiotherapy for squamous cell carcinoma of the maxillary sinus: analysis of local control and late complications.
  • This retrospective study was conducted to analyze the local control and late complications in patients with squamous cell carcinoma of the maxillary sinus treated with postoperative radiation therapy following surgery.
  • Between 1979 and 1998, 41 patients with squamous cell carcinoma of the maxillary sinus were treated with postoperative irradiation following partial or total maxillectomy.
  • Sixteen patients received preoperative intraarterial chemotherapy.
  • The total dose to the primary tumor bed was 40-70 Gy (median: 54 Gy) with a fraction size of 2 Gy.
  • The median follow-up time of the surviving patients was 93 months (range: 25-179 months).
  • For the patients with negative surgical margins, 8 of 9 (89%) patients achieved local control with a dose of 50-54 Gy, while 7 of 10 (70%) patients with microscopically positive margins achieved local control with a dose of 60-64 Gy.
  • There were 11 late complications found in 9 patients; bone necrosis in 2, soft tissue necrosis in 2, trisumus: 2, cellulitis in 1, retinopathy in 1, and vision impairment in 3 patients.
  • A total dose of 60 Gy or more was administered in all patients who suffered late complications except for 2 patients with vision impairment.
  • These results indicated that an optimal dose of postoperative irradiation according to the surgical margin status was necessary to achieve local control for squamous cell carcinoma of the maxillary sinus following surgery.
  • For patients with negative surgical margins, a total dose of 50-54 Gy in conventional fractionation was appropriate to achieve local control as well as to reduce late complications.
  • On the other hand, a dose of 60 Gy or more was required for the patients with microscopic positive margins.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Neoplasm Recurrence, Local / epidemiology. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Aged. Cellulitis / etiology. Chemotherapy, Adjuvant. Combined Modality Therapy. Eye Diseases / epidemiology. Eye Diseases / etiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Necrosis. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Time Factors. Trismus / etiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11182047.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


8. Isobe K, Uno T, Hanazawa T, Kawakami H, Yamamoto S, Suzuki H, Iida Y, Ueno N, Okamoto Y, Ito H: Preoperative chemotherapy and radiation therapy for squamous cell carcinoma of the maxillary sinus. Jpn J Clin Oncol; 2005 Nov;35(11):633-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemotherapy and radiation therapy for squamous cell carcinoma of the maxillary sinus.
  • OBJECTIVE: This study was undertaken to assess the prognostic factors for the management of squamous cell carcinoma (SCC) of the maxillary sinus, who received preoperative chemotherapy and radiation therapy (RT).
  • We also elucidated the appropriate sequence of chemotherapy.
  • METHODS: A total of 124 patients (median age 62 years) with SCC of the maxillary sinus were analysed retrospectively.
  • Thirty-nine patients received neoadjuvant chemotherapy (NA), 38 patients received concurrent chemoradiotherapy (CRT) and 47 patients received NA followed by CRT.
  • The median dose of RT was 60 Gy.
  • However, any chemotherapy sequence was not associated with the treatment outcome.
  • CONCLUSIONS: This study suggests that both surgery and T stage are important prognostic factors for LCP and OAS in the management of SCC of the maxillary sinus.
  • The appropriate sequence of chemotherapy remains to be elucidated in the future study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Peplomycin / administration & dosage. Prognosis. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275677.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 56H9L80NIZ / Peplomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Nishimura G, Tsukuda M, Mikami Y, Matsuda H, Horiuchi C, Satake K, Taguchi T, Takahashi M, Kawakami M, Hanamura H, Watanabe M, Utsumi A: The efficacy and safety of concurrent chemoradiotherapy for maxillary sinus squamous cell carcinoma patients. Auris Nasus Larynx; 2009 Oct;36(5):547-54
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy and safety of concurrent chemoradiotherapy for maxillary sinus squamous cell carcinoma patients.
  • OBJECTIVE: Combined treatment modality, e.g., definitive surgery followed by radiotherapy (RT) and definitive RT with concurrent chemotherapy, has been applied for advanced maxillary sinus squamous cell carcinoma (MSSCC) patients to obtain a better survival with organ preservation in Japan.
  • The median follow-up time was 66.1 months.
  • All the patients had received a combined treatment consisting of definitive surgery, RT, and intra-arterial or systemic chemotherapy.
  • Since 1998, concurrent chemoradiotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin regimen (CCRT-PFML) instead of neo-adjuvant chemotherapy has been applied.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy / adverse effects. Maxillary Sinus. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Kaplan-Meier Estimate. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Neoadjuvant Therapy. Organ Preservation / methods. Retrospective Studies. Tegafur / administration & dosage. Treatment Outcome. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097833.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


10. Fujishiro Y, Nakao K, Watanabe K, Ebihara Y, Nakamura N, Mori H, Hayashi N, Asakage T: A new aspect of tri-modal therapy with superselective intra-arterial chemotherapy in maxillary sinus carcinoma. Acta Otolaryngol Suppl; 2007 Dec;(559):151-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new aspect of tri-modal therapy with superselective intra-arterial chemotherapy in maxillary sinus carcinoma.
  • OBJECTIVE: A wide variety of modalities, including surgery, radiotherapy, and chemotherapy, alone or in combination, have been reported for the treatment of maxillary sinus cancer.
  • However, there is still much controversy with regard to the optimum treatment to obtain better local control and acceptable preservation of shape and function.
  • Since 2001, we have performed superselective intra-arterial infusion chemotherapy in combination with radiotherapy and surgery aiming at a higher local control rate.
  • The therapeutic design consisted of weekly intra-arterial infusion of high dose CDDP with concomitant radiotherapy and planned surgery performed during chemo-radiation therapy.
  • From June 2001 to January 2004, 14 patients with squamous cell carcinoma of maxillary sinus underwent this treatment procedure at the University of Tokyo Hospital.
  • RESULTS: The local response rate with this combined therapy was 85.7%.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Carcinoma / pathology. Cisplatin / therapeutic use. Maxillary Sinus / pathology. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intra-Arterial. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340587.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Kim GE, Chang SK, Lee SW, Pyo HR, Choi EC, Roh JK, Keum KC, Lee CG, Suh CO: Neoadjuvant chemotherapy and radiation for inoperable carcinoma of the maxillary antrum: a matched-control study. Am J Clin Oncol; 2000 Jun;23(3):301-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy and radiation for inoperable carcinoma of the maxillary antrum: a matched-control study.
  • A matched-control study comparing standard radiotherapy versus neoadjuvant chemotherapy and radiation was undertaken to clarify the effects of neoadjuvant systemic chemotherapy for locally advanced squamous cell carcinoma of the maxillary antrum.
  • Thirty-four patients with inoperable maxillary cancer were treated with neoadjuvant chemotherapy and radiotherapy (Group II).
  • Before starting radiotherapy, all patients in Group II received two or three cycles of neoadjuvant chemotherapy consisting of cisplatin and a 5-day continuous infusion of 5-fluorouracil with or without intravenous injection of vinblastine.
  • Radiation doses ranged from 66 Gy to 75 Gy (median, 70 Gy).
  • Despite a higher response rate to neoadjuvant chemotherapy, the recurrence rate and patterns of treatment failure were not influenced by the addition of neoadjuvant chemotherapy.
  • In most cases, neoadjuvant chemotherapy did not interfere with subsequent radiotherapy, and radiation-induced late complications occurred equally in both treatment groups.
  • After a median follow-up of 48 months, there was no significant difference in 5-year actuarial survival or disease-free survival between the two treatment groups.
  • Radiation alone for inoperable maxillary cancer was clearly suboptimal for improving local control and survival rate, but neoadjuvant chemotherapy in addition to standard radiotherapy failed to demonstrate any therapeutic advantage over radiation alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Treatment Failure

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10857899.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 28
  •  go-up   go-down


12. Yamamoto K, Obara S, Mishima K, Nakamura H, Yoshimura Y: [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1]. Gan To Kagaku Ryoho; 2004 Apr;31(4):635-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1].
  • We report a case of advanced squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to oral chemotherapy with TS-1.
  • We carried out chemotherapy with TS-1 50 mg/day, without surgical treatment.
  • Adverse drug reactions, including vomiting, leukopenia and thrombopenia, forced a stop of the administration of TS-1.
  • Although she finally died of in senescence 2 months from the cease of administration, there was no recurrence of the cancer at the time.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Gingival Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Drug Combinations. Female. Humans. Leukopenia / chemically induced. Mouth Mucosa / pathology. Neoplasm Invasiveness. Remission Induction. Thrombocytopenia / chemically induced. Vomiting, Anticipatory / etiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114716.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


13. Ashraf M, Biswas J, Dam A, Bhowmick A, Jha, Sing V, Nayak S: Results of Treatment of Squamous Cell Carcinoma of Maxillary Sinus: A 26-Year Experience. World J Oncol; 2010 Feb;1(1):28-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of Treatment of Squamous Cell Carcinoma of Maxillary Sinus: A 26-Year Experience.
  • Background: Five-year survival in squamous cell carcinoma of maxillary antrum is low.
  • This article examines the results of various approaches to treatment as given in our hospital in past 26 years.
  • Methods: From 1979 to 2005, 379 patients with squamous cell carcinoma of maxillary antrum managed with curative intent were studied.
  • Treatment to the primary site comprised of surgery (Sx) and radiation therapy (RT) in 284 patients, RT alone in 57 patients and chemotherapy (CTx) with radiotherapy in 38 patients.
  • Conclusions: The type of treatment to the primary site is an important determinant of survival and local control.
  • Surgery with radiation is a better treatment option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Otolaryngol. 1993 Apr;22(2):86-90 [8515523.001]
  • [Cites] Am J Surg. 1965 Oct;110(4):552-6 [5825167.001]
  • [Cites] J Surg Oncol. 1989 Feb;40(2):97-9 [2783752.001]
  • [Cites] JAMA. 1971 Oct 25;218(4):553-8 [5171003.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Jun;8(6):1045-9 [7107433.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):691-702 [17161557.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2790-4 [7139570.001]
  • [Cites] Head Neck Surg. 1979 Sep-Oct;2(1):3-11 [400658.001]
  • [Cites] J Surg Oncol. 1988 Jun;38(2):101-3 [3379963.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):449-56 [2674073.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1981 Jun;7(6):743-6 [6793543.001]
  • [Cites] Ai Zheng. 2004 Nov;23(11 Suppl):1546-50 [15566677.001]
  • [Cites] Br J Oral Maxillofac Surg. 1990 Dec;28(6):390-2 [2279038.001]
  • [Cites] CA Cancer J Clin. 1970 Jan-Feb;20(1):11-23 [5005751.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):283-9 [9308929.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):457-65 [9690538.001]
  • [Cites] Acta Otorrinolaringol Esp. 2008 Jan;59(1):6-10 [18215383.001]
  • [Cites] Head Neck. 2000 Mar;22(2):164-9 [10679904.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Sep;119(9):964-9 [8357597.001]
  • [Cites] Cancer. 1986 Jun 15;57(12):2261-6 [3697928.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Nov;18(11):1069-74 [6891650.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):27-35 [10924968.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1052-5 [4016696.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):679-88 [3338033.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):657-61 [1730116.001]
  • [Cites] BMJ. 1991 Jan 26;302(6770):193-4 [1998756.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):467-76 [2674075.001]
  • [Cites] Lancet. 1974 Feb 23;1(7852):277-9 [4130470.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):338-43 [18207030.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):719-30 [17543999.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Arch Otolaryngol. 1981 Jan;107(1):48-51 [7469880.001]
  • [Cites] Radiother Oncol. 1991 Jul;21(3):193-200 [1924855.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 May;24 Suppl 1:52-9 [9210888.001]
  • [Cites] Cancer. 1969 Oct;24(4):730-9 [5821758.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1360-4 [6193854.001]
  • (PMID = 29147176.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Antrum / Maxillary / Second primary / Squamous
  •  go-up   go-down


14. Watanabe A, Taniguchi M, Kawabori S: [A case of a 91-year-old woman with maxillary sinus carcinoma who achieved a complete response to chemoradiotherapy with intra-arterial administration of docetaxel]. Gan To Kagaku Ryoho; 2003 Nov;30(12):1941-3
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of a 91-year-old woman with maxillary sinus carcinoma who achieved a complete response to chemoradiotherapy with intra-arterial administration of docetaxel].
  • We treated a 91-year-old woman with advanced maxillary sinus carcinoma who achieved a complete response to chemoradiotherapy with intra-arterial administration of docetaxel.
  • After treatment, pathological examination of a biopsy specimen from the maxillary sinus revealed no residual tumor, and a posttreatment CT scan showed no tumor.
  • We conclude that chemoradiotherapy using intramaxillary infusion with docetaxel would be useful for maxillary sinus squamous cell carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / radiotherapy. Taxoids / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Infusions, Intra-Arterial. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14650963.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


15. Tiwari R, Hardillo JA, Mehta D, Slotman B, Tobi H, Croonenburg E, van der Waal I, Snow GB: Squamous cell carcinoma of maxillary sinus. Head Neck; 2000 Mar;22(2):164-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of maxillary sinus.
  • BACKGROUND: Medical records of 43 patients with histologically proved diagnosis of squamous cell carcinoma who were treated between the years 1975 and 1994 at the department of Otolaryngology Head Neck Surgery, VU Amsterdam were examined.
  • Thirty-eight patients were treated for cure, nine were treated with chemotherapy followed by external beam radiotherapy, and 28 patients were treated with surgery followed by postoperative radiotherapy.
  • RESULTS: Eighty-three percent of the tumours were in stage III or stage IV at the time of first presentation.
  • Cervical nodal metastases were present in 4.1% at the time of presentation.
  • Thirty-seven percent of the patients survived 2 years after chemotherapy followed by radiotherapy.
  • CONCLUSIONS: Squamous cell carcinoma continues to be diagnosed late.
  • Surgery followed by radiotherapy remains the treatment of choice.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Maxillary Sinus Neoplasms / diagnosis. Maxillary Sinus Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 John Wiley & Sons, Inc. Head Neck 22: 164-169, 2000.
  • (PMID = 10679904.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


16. Kawashima M, Ogino T, Hayashi R, Ishikura S, Nihei K, Ito Y, Ikeda H, Ebihara S, Itai Y: Influence of postsurgical residual tumor volume on local control in radiotherapy for maxillary sinus cancer. Jpn J Clin Oncol; 2001 May;31(5):195-202
Genetic Alliance. consumer health - Sinus cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of postsurgical residual tumor volume on local control in radiotherapy for maxillary sinus cancer.
  • BACKGROUND: The aim was to study the influence of postsurgical gross residual tumor volume on local control of maxillary sinus cancer treated with radiotherapy combined with debulking surgery.
  • METHODS: Forty-three patients who underwent combined surgery and radiotherapy (50-72 Gy, median 60 Gy) for squamous cell carcinoma of the maxillary sinus were reviewed.
  • Multivariate analysis showed that GRTV (P = 0.002) and histological differentiation (poorly differentiated histology was favorable, P = 0.035) were independent prognostic factors and that intra-arterial chemotherapy and administered total dose were not.
  • Local control in groups A and B significantly depended on the total dose of radiotherapy, with 2-year control rates of patients receiving 50 Gy (n = 6) and > or = 60 Gy (n = 27) of 17% vs 79%, respectively (P < 0.001).
  • CONCLUSIONS: Our data suggest that adequate, not complete, debulking associated with a total radiotherapy dose of > or = 60 Gy can provide satisfactory local control for patients with squamous cell carcinoma of the maxillary sinus.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Maxillary Sinus / surgery. Maxillary Sinus Neoplasms / pathology. Maxillary Sinus Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11450993.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Cantù G, Bimbi G, Fabiani F, Guzzo M, Mattavelli F, Pizzi N, Riccio S, Squadrelli M: [Lymph node metastases in paranasal sinus carcinoma: prognostic value and treatment]. Acta Otorhinolaryngol Ital; 2002 Oct;22(5):273-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymph node metastases in paranasal sinus carcinoma: prognostic value and treatment].
  • The purpose of this report is to assess, on the basis of a sizeable study, the prognostic value of lymph node metastases in paranasal sinus carcinoma and, in particular, in squamous cell carcinoma of the maxillary sinus.
  • We have reviewed the charts of 601 cases of paranasal sinus carcinoma between 1970 and 1999.
  • All of the patients were treated surgically, alone or associated with chemotherapy and/or radiotherapy.
  • The maxillary sinus tumors numbered 379 (153 squamous cell carcinomas, 15 undifferentiated carcinomas, 94 adenoid cystic carcinomas, 19 adenocarcinomas, 98 mesenchymal tumors and rare forms) and the ethmoidal tumors were 222 (117 adenocarcinomas, 27 squamous cell carcinomas, 16 adenoid cystic carcinomas, 13 undifferentiated carcinomas, 49 other histological forms).
  • Lymph node metastases in ethmoidal tumors were rare, with the exception of undifferentiated carcinoma (46.1%).
  • The percentages of metastatic squamous cell carcinoma of the maxillary sinus upon presentation were: T2 15.5%, T3 7%, and T4 4%.
  • The metastases successive to treatment of the primary tumor were: T2 16.9%, T3 8.8%, and T4 12%.
  • The NED survival rate at least two years after T therapy in patients free from metastases was 50.4%, against 25% in those with initial or distant metastases (T2 72.9% vs. 30.4%, T3 37.5% vs. 22.2%, and T4 28.6% vs. 0%).
  • In conclusion, squamous cell carcinomas of the maxillary sinus which have extended to the oral cavity (T2) show greater lymph node propagation than those of the superoposterior portion (T3-T4).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Maxillary Sinus / radiation effects. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12510338.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Muramatsu Y, Hasegawa Y, Fukano H, Ogawa T, Namuba M, Mouri K, Fujimoto Y, Matsuura H, Takai Y, Mori M: Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses. Anticancer Res; 2000 Jan-Feb;20(1A):257-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein immunoreactivity in head and neck carcinomas; special reference to clinical behaviors and chemotherapy responses.
  • Metallothionein (MT), has selectively binding affinity for heavy metal ions and over expression of MT has a potential against resistance for CDDP anticancer agents and radiation treatment.
  • The role of MT immunoreactivity of squamous cell carcinoma in oral and pharyngeal regions (n = 28) and in the maxillary sinus region (n = 3) was evaluated for distribution patterns of MT and clinicopathologic behaviors.
  • MT immunoreactivity was expressed in both tumor cell cytoplasm and nuclei, and showed heterogeneous localization in tumor epithelial cells and in the stroma.
  • In oral and pharyngeal carcinomas (n = 28), MT positive cell index in treated cases (n = 11) was 17.85% and that in non treated tumors (n = 17) was 25.19%.
  • In maxillary sinus carcinomas (n = 3), MT positive index was 4.56% and showed lowers levels as compacted to other SCC sites.
  • [MeSH-major] Carcinoma, Squamous Cell / chemistry. Head and Neck Neoplasms / chemistry. Metallothionein / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / chemistry. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cell Differentiation. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Resistance, Neoplasm. Female. Fluorouracil / administration & dosage. Gingival Neoplasms / chemistry. Gingival Neoplasms / pathology. Gingival Neoplasms / therapy. Humans. Hypopharyngeal Neoplasms / chemistry. Hypopharyngeal Neoplasms / pathology. Hypopharyngeal Neoplasms / therapy. Lymphatic Metastasis. Male. Maxillary Sinus Neoplasms / chemistry. Maxillary Sinus Neoplasms / pathology. Maxillary Sinus Neoplasms / therapy. Middle Aged. Mouth Mucosa / chemistry. Tongue Neoplasms / chemistry. Tongue Neoplasms / pathology. Tongue Neoplasms / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10769664.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 9038-94-2 / Metallothionein; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Kovács AF, Eberlein K, Hülsmann T: Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus. Oral Maxillofac Surg; 2009 Jun;13(2):87-93
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
  • PURPOSE: Induction chemotherapy with Taxotere, cisplatin, and 5-fluororacil (TPF) was mainly used in hypopharyngeal and laryngeal cancer patients for larynx preservation.
  • This study aimed to assess feasibility and toxicity in oral cavity and maxillary sinus cancer patients.
  • PATIENTS AND METHODS: Between 2003 and 2008, 21 patients (18 male, three female; mean age 58 years; 15 patients Eastern Cooperative Oncology Group > or =1) suffering from advanced squamous cell cancers of the oral cavity (seven primaries, eight locoregional recurrences) and the maxillary sinus (six patients) were prospectively treated with three cycles of TPF (q3w) and were scheduled to undergo definitive chemoradiation.
  • Reasons for incomplete treatment were tumor progression, edema, seizure, bad general condition, sepsis, pneumonia (each once).
  • The infections led to two treatment-related deaths (9.5%).
  • Ten patients underwent a definitive chemoradiation or radiation (47.6%).
  • After a mean observation time of 17 months, nine patients are alive; one of them developed a local recurrence.
  • CONCLUSIONS: Chemotherapy with TPF is a highly effective treatment with considerable toxicity that needs special expertise which is best assured in a multidisciplinary setting.
  • A target for organ preservation could be the maxillary sinus; due to tumor regression in advanced oral tongue cancer, consecutively, a reduced function has to be encountered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Maxillary Sinus Neoplasms / drug therapy. Mouth Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Disease Progression. Feasibility Studies. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Opportunistic Infections / etiology. Pilot Projects. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction. Stomatitis / chemically induced. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2009 May;20(5):921-7 [19179556.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2873-8 [16782926.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):485-8 [12393990.001]
  • [Cites] Mund Kiefer Gesichtschir. 2006 May;10(3):168-77 [16604330.001]
  • [Cites] Oral Oncol. 2006 Aug;42(7):675-84 [16731029.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jun;136(6):1003-9 [17547996.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):481-7 [15145166.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):585-90 [16739325.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):75-85, viii [15649500.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • (PMID = 19430823.001).
  • [ISSN] 1865-1550
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Taxoids; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; TPF protocol
  •  go-up   go-down


20. Ampil FL, Heldmann M, Ibrahim AM, Balfour EL: Involvement of the cavernous sinus by malignant (extracranial) tumour: palliation in six cases without surgery. J Craniomaxillofac Surg; 2000 Jun;28(3):161-4
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of the cavernous sinus by malignant (extracranial) tumour: palliation in six cases without surgery.
  • Involvement of the cavernous sinus region due to haematogenous spread or by local extension of a malignant head and neck tumour does not occur frequently.
  • Six patients were treated by external beam radiation with (n=3) or without neoadjuvant chemotherapy between December 1989 and February 1996.
  • Complete resolution of cranial nerve deficits after therapy occurred in two of the four patients with only three individuals having been evaluable.
  • [MeSH-major] Cavernous Sinus. Cranial Nerve Neoplasms / secondary. Palliative Care. Skull Neoplasms / secondary. Skull Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Female. Humans. Male. Maxillary Sinus Neoplasms / pathology. Middle Aged. Nasopharyngeal Neoplasms / pathology. Prostatic Neoplasms / pathology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 European Association for Cranio-Maxillofacial Surgery.
  • (PMID = 10964552.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SCOTLAND
  •  go-up   go-down


21. Schiefke F, Hildebrandt G, Pohlmann S, Heinicke F, Hemprich A, Frerich B: Combination of surgical resection and HDR-brachytherapy in patients with recurrent or advanced head and neck carcinomas. J Craniomaxillofac Surg; 2008 Jul;36(5):285-92
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Due to the limited therapeutic options, the management of previously pre-treated recurrent head and neck carcinomas remains a challenging problem.
  • MATERIAL AND METHODS: From 2000 to 2006, 13 patients with pre-treated, recurrent head and neck cancer (oral, maxillary sinus, lips) were treated in a curative approach by resection the recurrent tumour and HDR-BT.
  • Conventional radiotherapy and chemotherapy were added as required.
  • Additionally 5 patients, who received this combination therapy for primary carcinomas were included in this report observation in order to evaluate the rate of complications and adverse effects.
  • Patients treated for primary carcinoma had a mean survival of 34.5 months.
  • Four out of five (80%) patients with primary head and neck cancer were alive and without evidence of disease 2 years after treatment.
  • There were no relevant complications concerning tissue transfer.
  • A simultaneous microvascular defect reconstruction provides tissue cover for brachytherapy.
  • [MeSH-major] Brachytherapy / methods. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / radiotherapy. Head and Neck Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Dose Fractionation. Female. Humans. Kaplan-Meier Estimate. Male. Microsurgery. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Remission Induction. Reoperation / adverse effects. Salvage Therapy / methods. Surgical Flaps

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18353667.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


22. Adachi M, Shibata A, Hayashi M, Satoh D, Miyasaka T, Yanai C, Kawatsu N, Yagishita H, Ogino Y, Yamashita N, Suzuki M: [Combined preoperative therapy for oral cancer with nedaplatin and radiation]. Gan To Kagaku Ryoho; 2002 Mar;29(3):465-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined preoperative therapy for oral cancer with nedaplatin and radiation].
  • We performed preoperative combined therapy using nedaplatin (CDGP) and radiation in 12 patients with squamous cell carcinoma originating from the oral cavity and maxillary sinus, and examined for any adverse events that may have occurred during this therapeutic regimen.
  • Regarding the irradiation, external irradiation utilizing a 6 MV linac (linear accelerator) at a dose of 2.0 Gy/day was performed 5 times a week, with the target total radiation dose set at 40 Gy.
  • Two subjects developed grade 3 leucopenia and were thus given granulocyte colony stimulating factor (G-CSF).
  • These findings are therefore considered to provide evidence supporting the safety of this combination therapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Preoperative Care
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Radiotherapy, High-Energy

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11915741.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin
  •  go-up   go-down


23. Yanamoto S, Kawasaki G, Yoshida H, Yoshitomi I, Iwamoto T, Mizuno A, Fujita S: Rapidly growing mass of the anterior maxillary gingiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug;104(2):153-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly growing mass of the anterior maxillary gingiva.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Gingival Neoplasms / pathology. Maxilla / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Diagnosis, Differential. Granulomatosis with Polyangiitis / diagnosis. Humans. Male. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / pathology. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Mycoses / diagnosis. Nose Neoplasms / drug therapy. Nose Neoplasms / pathology. Nose Neoplasms / radiotherapy. Nose Neoplasms / surgery. Palatal Neoplasms / drug therapy. Palatal Neoplasms / pathology. Palatal Neoplasms / radiotherapy. Palatal Neoplasms / surgery. Radiotherapy, Adjuvant. Tuberculosis, Oral / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17449292.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement